The markers that differentiate these entities include lymphoma markers (e. g., cluster of differentiation [CD] 20, CD79a, BCL2, CD10, BCL6, multiple myeloma oncogene), while in HT, epithelial markers, such as cytokeratin are positive. This evidence concerns the gene CD79A and lymphoma.